Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIZEM CD vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in dilation of coronary arteries and peripheral arterioles, and decreased myocardial contractility and conduction velocity.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Hypertension,Chronic stable angina,Variant angina
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Hypertension: 180-360 mg once daily orally. Angina: 120-360 mg once daily orally. Maximum dose: 480 mg/day.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life: 6-8 hours (single dose), prolonged to 10-15 hours with multiple dosing or in elderly/hepatic impairment. Clinical context: Therapeutic steady-state achieved in 2-4 days.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Hepatic via CYP3A4; also undergoes deacetylation; substrate of P-glycoprotein.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal: ~2-4% (unchanged), Hepatic metabolism to multiple metabolites; ~65% renal (metabolites), ~35% fecal/biliary. Total clearance: 5-7 m L/kg/min.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
70-80% bound primarily to albumin (70%), also alpha-1 acid glycoprotein (10%). Binding saturable at high concentrations.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
Approximately 5.3 L/kg. Meaning: Extensive tissue distribution (3-5 L/kg); reflects high lipophilicity and wide distribution beyond plasma.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Extended-release (Cardizem CD): ~40% (range 35-45%) due to extensive first-pass metabolism. Immediate-release: ~40-50%. IV: 100%.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No specific GFR-based adjustment required, but use caution in severe renal impairment (Cr Cl <30 m L/min).
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh Class A: start with 120 mg once daily. Child-Pugh Class B: start with 120 mg once daily, titrate cautiously. Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Not approved for pediatric use; safety and efficacy not established.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Start at lower end of dosing range (120 mg once daily) due to increased risk of hypotension and bradycardia; titrate slowly.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None
None
May cause hypotension,Risk of heart failure exacerbation in patients with impaired ventricular function,May slow AV conduction, leading to bradycardia or AV block,Hepatic and renal impairment caution,May exacerbate symptoms in patients with hypertrophic cardiomyopathy
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Sick sinus syndrome (except in presence of functioning ventricular pacemaker),Second- or third-degree AV block (except in presence of functioning ventricular pacemaker),Hypotension (systolic < 90 mm Hg),Acute myocardial infarction with pulmonary congestion,Known hypersensitivity to diltiazem
None
Grapefruit juice may increase diltiazem serum concentrations; avoid concurrent ingestion. Alcohol may enhance hypotensive effects. No significant food restrictions otherwise.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
Diltiazem, the active ingredient in Cardizem CD, is classified as Pregnancy Category C. Animal studies have demonstrated embryotoxicity and teratogenicity (skeletal abnormalities) at doses 5-10 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. In humans, exposure during the first trimester may be associated with a small increased risk of congenital anomalies, particularly cardiac defects, though data are limited. During the second and third trimesters, use may be associated with potential risks of fetal growth restriction and preterm labor due to maternal hypotension and decreased uteroplacental perfusion. The drug should only be used if the potential benefit justifies the potential risk to the fetus.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted into human milk at low concentrations; the milk-to-plasma (M/P) ratio is approximately 0.8. Limited data suggest that the estimated infant daily dose is less than 1% of the maternal weight-adjusted dose. While adverse effects in breastfed infants have not been reported, caution is advised due to potential for cardiovascular effects. The manufacturer recommends discontinuing breastfeeding or the drug, considering the importance of the drug to the mother.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Pregnancy-induced increases in plasma volume and hepatic metabolism may reduce diltiazem concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic studies in pregnant women are lacking. Clinical monitoring of therapeutic effect (e.g., blood pressure control) should guide dosing; gradual titration is recommended, and doses may need to be increased based on response. Avoid abrupt discontinuation.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Diltiazem (Cardizem CD) is a nondihydropyridine calcium channel blocker; use with caution in patients with systolic heart failure (HFr EF) due to negative inotropic effects. Avoid concurrent use with beta-blockers due to risk of bradycardia and heart block. May increase dugoxin levels; monitor digoxin levels. Contraindicated in sick sinus syndrome or second/third-degree AV block without pacemaker. Also inhibits CYP3A4; monitor for interactions with statins (e.g., simvastatin dose limit 10 mg).
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take capsule whole; do not crush or chew. May be taken without regard to meals.,Do not stop abruptly; gradual taper advised to avoid rebound hypertension or ischemia.,Report symptoms of bradycardia (dizziness, fainting) or heart failure (swelling, shortness of breath).,Avoid grapefruit juice as it may increase drug levels and risk of side effects.,Use sunscreen and protective clothing due to possible photosensitivity.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIZEM CD vs AMVAZ, answered by our medical review team.
CARDIZEM CD is a Calcium Channel Blocker that works by Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in dilation of coronary arteries and peripheral arterioles, and decreased myocardial contractility and conduction velocity.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIZEM CD and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIZEM CD is: Hypertension: 180-360 mg once daily orally. Angina: 120-360 mg once daily orally. Maximum dose: 480 mg/day.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIZEM CD and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIZEM CD is classified as Category C. Diltiazem, the active ingredient in Cardizem CD, is classified as Pregnancy Category C. Animal studies have demonstrated embryotoxicity and teratogenicity (skeletal abnormalities) . AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.